# CCTN - CONTRACEPTIVE CLINICAL TRIAL NETWORK  - REVERSIBLE CONTRACEPTIVE

> **NIH NIH N01** · JOHNS HOPKINS UNIVERSITY · 2020 · $131,223

## Abstract

The Contraceptive Discovery and Development Branch (CDDB) under the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is committed to develop new methods that are long-acting reversible contraceptives (LARCs) that can provide safe and effective contraception for women who may have risk factors against some contraceptive products as well as reduce the risk of venous thromboembolism (VTE). The copper intrauteril1e devices ([UDs) are examples of intrauterine systems that provide long-acting contraceptive benefits without exogenous hormones or disruption of the regular menstrual cycle.
LARC methods include IUDs, implants, or long acting vaginal rings. LARC methods are more effective than daily, weekly or monthly products because they are less prone to user error. IUDs <Hld  implants have an effectiveness rate that is in the top tier for typical use (>99% effective). Development of new LARC methods is a high priority for the CDDB.
Of the currently approved LARC methods, copper-containing IUDs are the only highly effective reversible methods that do not involve administration of hormones and do not catJse irregular or unscheduled bleeding patterns in women. These properties make a copper IUD an ideal method for women who do not wish to take or cannot take hormonal contrnccptive methods. Products containing the synthetic estrogen and ethinyl estradiol have been associ!:lted with a dose-dependent increase in VTE. Copper IUDs do not increase the risk ofVTE and would therefore be suitable for use by women who have an increased risk ofVTE, such as obese women, pregnant women and women with Leiden Factor V.  Currently there is one copper IUD, Copper T380 (Paragard®),  available  in the US. This TUD is associated with pain on insertion and with a high incidence cramping and  heavy bleeding during subsequent months of use. The number one reason for discontinuation of the method is the incidence of heavy bleeding and cramping associated with tbe device. Preliminary data from some· studies indicate that newer copper IUDs
may be associated with a lower incidence of heavy bleeding and/or cramping and some devices may have less pain with insertion. It is unclear if any of the newer devices could have a lower incidence of expulsion  in some populations of women.

In order to evaluate if new LARC products could be effective for contraception, and have a lower incidence of side effects that might lead to discontinuation, a prospective randomized controlled clinical trial will be conducted  in the NICHD Contraceptive Clinical Trials Network (CCTN). The products proposed to be tested are LARCs'as described above, These products will be compared to the currently available LARC methods.

## Key facts

- **NIH application ID:** 10109004
- **Project number:** 275201300004I-P00002-27500003-1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** ANNE BURKE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $131,223
- **Award type:** —
- **Project period:** 2015-09-25 → 2022-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10109004

## Citation

> US National Institutes of Health, RePORTER application 10109004, CCTN - CONTRACEPTIVE CLINICAL TRIAL NETWORK  - REVERSIBLE CONTRACEPTIVE (275201300004I-P00002-27500003-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10109004. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*